Role of PARP Inhibition in Recurrent Ovarian Cancer

Video

Recent Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
Related Content
Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Early Palliative Care May Increase QOL in Ovarian Cancer Decedents Near EOL

Tim Cortese
November 4th 2024
Article

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer | Image Credit: © Lars Neumann - stock.adobe.com.

Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer

Russ Conroy
October 18th 2024
Article

Updated findings from RAMP 201 show that avutometinib/defactinib is generally well tolerated among those with low-grade serous ovarian cancer.

Population Testing to Prevent Gynecologic Cancers

Population Testing to Prevent Gynecologic Cancers

Ranjit Manchanda, MD, PhD
September 12th 2018
Podcast

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

FDA Approves Novel Formulation for Breast and Ovarian Cancers

Ariana Pelosci
June 28th 2024
Article

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer

No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer

Silas Inman
June 2nd 2024
Article

There was no benefit derived from adding atezolizumab to chemotherapy and bevacizumab in patients with recurrent ovarian cancer.